NCT02822742

A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study

A Phase III, Open-label, Single-arm, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension Who Are Non-/Low-responders to Latanoprost Ophthalmic Solution: FUJI Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Santen Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purposes of this study are to investigate the effect of intraocular pressure lowering efficacy and safety of DE-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension who are non-/low-responders to latanoprost ophthalmic solution.

Conditions

• Primary Open Angle Glaucoma or Ocular Hypertension

Interventions

Type	Name	Description
DRUG	DE-117 ophthalmic solution
DRUG	Latanoprost ophthalmic solution 0.005%

Timeline

• Start date: 2016-07-02
• Primary completion: 2017-04-28
• Completion: 2017-04-28
• First posted: 2016-07-04
• Last updated: 2017-11-20

Locations

1 site across 1 country: Japan